Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s: 1 nM, 7 nM, 120 nM). It also suppresses RET tyrosine kinase, PDGFRβ, and Flt1 (IC50s: 7 nM, 3 nM, and 32 nM).
BAY-155 is a powerful and selective menin-MLL inhibitor, exhibiting an IC 50 of 8 nM. It significantly down-regulates MEIS1 gene expression while up-regulating CD11b and MNDA genes. BAY-155 also demonstrates anti-proliferative effects in AML ALL (acute myeloid lymphoblastic leukemia) models [1].